By Abigail Townsend
Date: Thursday 07 Nov 2024
(Sharecast News) - Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.
Updating on current trading, the blue chip said it was "performing well", leaving it on track to grow 2024 revenue by between 6% and 8%. Core operating profit is forecast to...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news